When Will the Ozempic Lawsuit Be Settled? Timeline, Precedent, and What Plaintiffs Can Expect

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Based on pharmaceutical litigation precedent, the Ozempic gastroparesis lawsuits will likely reach initial settlement discussions between 2027 and 2029, with final resolution by 2030 to 2031
• The litigation is currently in multidistrict litigation (MDL) consolidation phase in the Eastern District of Pennsylvania, with bellwether trials expected to begin in late 2026 or early 2027
• Settlement amounts depend on injury severity, documented causation, and bellwether trial outcomes, with gastroparesis cases historically settling between $50,000 and $2.5 million per plaintiff
• No settlement is guaranteed; Novo Nordisk and Eli Lilly may choose to litigate individual cases through trial rather than accept a global settlement structure

Direct answer (40-60 words)

The Ozempic and GLP-1 gastroparesis lawsuits will likely reach settlement discussions between 2027 and 2029, based on pharmaceutical litigation precedent. Final resolution typically occurs 5 to 7 years after initial filing. The litigation entered MDL consolidation in February 2024, with bellwether trials expected in 2026 to 2027. Settlement timing depends on trial outcomes and manufacturer willingness to negotiate.

Table of contents

1. The current litigation status as of April 2026
2. The three-phase pharmaceutical settlement timeline
3. What bellwether trials are and why they determine settlement
4. Precedent: how long similar drug lawsuits took to settle
5. The factors that accelerate or delay settlement
6. What most articles get wrong about "average settlement amounts"
7. The decision tree: settle, opt out, or wait for trial
8. When you should NOT join the litigation
9. The gastroparesis severity spectrum and how it affects payout
10. What happens if Novo Nordisk refuses to settle
11. FAQ
12. Sources

The current litigation status as of April 2026

As of April 2026, the Ozempic and broader GLP-1 receptor agonist litigation is consolidated in multidistrict litigation (MDL No. 3094) in the U.S. District Court for the Eastern District of Pennsylvania under Judge Karen S. Marston. The MDL includes claims against Novo Nordisk (semaglutide products: Ozempic, Wegovy, Rybelsus) and Eli Lilly (tirzepatide products: Mounjaro, Zepbound).

The core allegation is failure to warn. Plaintiffs claim manufacturers knew or should have known that GLP-1 receptor agonists cause severe gastroparesis, intestinal obstruction, and ileus but failed to adequately warn prescribers and patients. The FDA label for semaglutide lists "delayed gastric emptying" under mechanism of action but does not list gastroparesis as an adverse event in the warnings section. Plaintiffs argue this constitutes inadequate disclosure.

The litigation timeline so far:

• August 2023: First complaints filed in state courts
• February 2024: MDL consolidation granted, cases transferred to Eastern District of Pennsylvania
• June 2024: First amended master complaint filed
• November 2024: Defendants filed motions to dismiss, arguing preemption and lack of causation
• March 2025: Court denied motions to dismiss on most counts, allowing failure-to-warn claims to proceed
• September 2025: Discovery phase began, including document production and expert witness disclosure
• April 2026 (current): Bellwether selection process underway, with first trials expected Q4 2026 or Q1 2027

The litigation is in the discovery and bellwether preparation phase. Settlement discussions typically do not begin in earnest until after the first 3 to 6 bellwether trials produce verdict data.

The three-phase pharmaceutical settlement timeline

Pharmaceutical product liability litigation follows a predictable three-phase arc. Understanding the phases helps set realistic expectations for when settlement might occur.

Phase 1: Consolidation and motion practice (12 to 24 months).

Plaintiffs file individual complaints in various jurisdictions. Defendants petition for MDL consolidation to streamline discovery and avoid duplicative rulings. The Judicial Panel on Multidistrict Litigation grants consolidation and assigns a single judge. Defendants file motions to dismiss. The court rules on threshold legal questions: preemption, causation standards, statute of limitations.

For the Ozempic litigation, this phase ran from August 2023 through March 2025 (19 months). The court's March 2025 denial of most dismissal motions moved the case into phase 2.

Phase 2: Discovery and bellwether trials (24 to 48 months).

Both sides exchange documents, depose witnesses, and disclose expert testimony. The court selects 6 to 12 "bellwether" cases representative of the broader plaintiff pool. These cases go to trial first. Bellwether verdicts establish the range of likely outcomes and inform settlement negotiations.

The Ozempic litigation entered phase 2 in mid-2025. Bellwether trials are expected to begin in late 2026 or early 2027. Assuming 3 to 6 bellwether trials over 18 to 24 months, this phase will likely extend through 2028.

Phase 3: Settlement negotiation and resolution (12 to 36 months).

After bellwether verdicts establish a pattern, defendants and plaintiffs' steering committee negotiate a global settlement structure. This may include a settlement fund, tiered payout based on injury severity, and claims administration process. Individual plaintiffs decide whether to accept the settlement or opt out and pursue individual trials.

For the Ozempic litigation, phase 3 will likely begin in 2028 or 2029, with final resolution by 2030 to 2031.

Total timeline from initial filing to final settlement: 5 to 7 years. The Ozempic litigation, filed in August 2023, fits this projection with expected resolution between 2028 and 2030.

What bellwether trials are and why they determine settlement

A bellwether trial is a representative case selected from the larger MDL pool and tried to verdict before a jury. The purpose is not to resolve that individual plaintiff's claim (though it does) but to test legal theories, gauge jury response, and establish valuation benchmarks.

The court and both parties jointly select bellwether cases to represent the diversity of claims: different injury severities, different drugs (Ozempic vs Wegovy vs Mounjaro), different patient demographics, different prescribing contexts (diabetes vs obesity).

Bellwether outcomes fall into three categories:

1. Plaintiff verdicts. Jury finds for the plaintiff and awards damages. This signals that the failure-to-warn theory is viable and juries are sympathetic. Defendants face pressure to settle before more verdicts accumulate.

1. Defense verdicts. Jury finds for the defendant, concluding that the warning was adequate or causation was not proven. This strengthens the defense position and may lead plaintiffs to accept lower settlement offers or drop claims.

1. Mixed verdicts. Some bellwether plaintiffs win, others lose. This is the most common outcome and typically leads to settlement negotiations because both sides face uncertainty.

Historical data from pharmaceutical MDLs shows that settlement discussions begin in earnest after 3 to 6 bellwether trials. If the first 3 trials all favor plaintiffs, defendants often move quickly to settlement to avoid a cascade of similar verdicts. If the first 3 trials favor defendants, plaintiffs' steering committee may lower settlement demands or shift strategy.

For the Ozempic litigation, bellwether trials are expected to begin in Q4 2026 or Q1 2027. Assuming 3 to 6 trials spaced 3 to 6 months apart, bellwether results will accumulate through 2027 and into 2028. Settlement discussions will likely begin in late 2027 or 2028, once a pattern emerges.

Precedent: how long similar drug lawsuits took to settle

Pharmaceutical product liability settlements provide a benchmark for the Ozempic litigation timeline. The table below summarizes recent high-profile cases:

Drug	Allegation	MDL filed	First settlement	Final resolution	Total time
Risperdal (risperidone)	Gynecomastia in boys	2012	2015	2019	7 years
Xarelto (rivaroxaban)	Uncontrollable bleeding	2014	2017	2019	5 years
Taxotere (docetaxel)	Permanent hair loss	2016	2019	2023	7 years
Elmiron (pentosan polysulfate)	Retinal damage	2020	2023	Ongoing	3+ years (partial)
Zantac (ranitidine)	NDMA contamination, cancer risk	2020	Dismissed 2022	N/A	N/A (no settlement)

The Risperdal litigation is instructive. The MDL was established in 2012. Bellwether trials began in 2015, with mixed results (some large plaintiff verdicts, some defense verdicts). Johnson & Johnson began settlement discussions in 2015 but did not finalize a global settlement structure until 2019. Total time: 7 years.

The Xarelto litigation moved faster. Bellwether trials in 2017 produced mostly defense verdicts, which led to a relatively quick settlement in 2019 to clear the docket. Total time: 5 years.

The Taxotere litigation followed the longer arc. Bellwether trials in 2019 produced plaintiff verdicts, but Sanofi resisted global settlement and litigated individual cases through 2023. Total time: 7 years, with some cases still pending.

The Zantac litigation is the cautionary example. The MDL was dismissed in 2022 after the court excluded plaintiffs' expert testimony on causation, finding it scientifically unreliable under Daubert standards. No settlement occurred. Thousands of cases were dismissed.

Based on this precedent, the Ozempic litigation will likely follow the 5 to 7 year timeline. The August 2023 filing date suggests resolution between 2028 and 2030. The key variable is bellwether trial outcomes. Strong plaintiff verdicts accelerate settlement. Defense verdicts or Daubert challenges to causation evidence could delay or prevent settlement.

The factors that accelerate or delay settlement

Several factors determine whether the Ozempic litigation settles quickly (5 years) or drags on (7+ years):

Factors that accelerate settlement:

1. Consistent plaintiff bellwether verdicts. If the first 3 to 6 bellwether trials produce plaintiff wins with substantial damages, Novo Nordisk and Eli Lilly face mounting liability and will likely negotiate.

1. Strong causation evidence. If plaintiffs' expert witnesses present compelling, scientifically rigorous evidence that GLP-1 agonists cause gastroparesis at rates significantly above baseline, courts are less likely to exclude the testimony and defendants are more likely to settle.

1. Regulatory action. If the FDA issues a safety communication or requires a black-box warning for gastroparesis, it strengthens plaintiffs' failure-to-warn claims and increases settlement pressure.

1. High plaintiff volume. As of April 2026, the MDL includes over 1,200 cases, with more being filed monthly. High volume increases administrative burden on defendants and courts, creating pressure to resolve claims efficiently.

1. Reputational risk. Prolonged litigation generates negative media coverage. Novo Nordisk and Eli Lilly may settle to protect brand reputation, especially as GLP-1 medications are blockbuster revenue drivers.

Factors that delay settlement:

1. Defense bellwether verdicts. If defendants win the first several bellwether trials, they have little incentive to settle and may choose to litigate each case individually.

1. Causation disputes. Gastroparesis has multiple causes (diabetes itself, other medications, idiopathic). If defendants successfully argue that plaintiffs cannot prove GLP-1 agonists caused their specific injury, settlement becomes less likely.

1. Daubert challenges. If the court excludes plaintiffs' expert testimony as unreliable under Daubert v. Merrell Dow Pharmaceuticals, the litigation may collapse (as happened with Zantac).

1. Preemption arguments. Defendants may argue that federal law preempts state failure-to-warn claims because the FDA approved the label. If courts accept this argument, claims are dismissed.

1. Manufacturer financial position. Novo Nordisk reported $30 billion in revenue in 2023, with semaglutide products accounting for over $20 billion. The company has the financial capacity to litigate indefinitely rather than settle.

The current trajectory suggests settlement is more likely than dismissal. The court denied most dismissal motions in March 2025, allowing failure-to-warn claims to proceed. Discovery is ongoing. Bellwether trials will determine the next phase.

What most articles get wrong about "average settlement amounts"

Most online articles cite "average settlement amounts" of $100,000 to $500,000 for Ozempic gastroparesis claims. These figures are speculative and misleading for three reasons:

1. No settlement has occurred yet.

As of April 2026, the Ozempic litigation has not produced a single settlement. The figures cited in online articles are projections based on other pharmaceutical settlements, not actual Ozempic payouts. Any article claiming to know the "average Ozempic settlement" is fabricating data.

2. Gastroparesis severity varies by orders of magnitude.

Gastroparesis ranges from mild (occasional nausea, manageable with diet changes) to severe (total gastric paralysis requiring feeding tube or gastric pacemaker). A plaintiff with mild symptoms that resolved after discontinuing the medication will receive far less (if anything) than a plaintiff with permanent gastroparesis requiring surgical intervention.

The settlement structure, if one emerges, will almost certainly tier payouts by injury severity. A reasonable projection based on precedent:

• Tier 1 (mild, transient gastroparesis): $10,000 to $50,000
• Tier 2 (moderate, persistent symptoms requiring ongoing treatment): $50,000 to $250,000
• Tier 3 (severe, requiring hospitalization or surgical intervention): $250,000 to $1 million
• Tier 4 (catastrophic, permanent feeding tube or gastric pacemaker): $1 million to $5 million

These are projections, not guarantees. Actual amounts depend on bellwether verdicts, which have not yet occurred.

3. Many plaintiffs will receive nothing.

Settlement structures typically require objective medical documentation of injury and a plausible causal link to the medication. Plaintiffs who cannot produce gastric emptying study results, endoscopy reports, or other diagnostic evidence may be excluded from settlement or offered nominal amounts.

In the Risperdal litigation, approximately 30% of plaintiffs who joined the MDL ultimately received no payout because they could not document injury severity or causation. The Ozempic litigation will likely follow a similar pattern.

The honest answer to "how much will I get?" is: it depends on injury severity, documentation quality, and whether you can prove the medication caused your specific symptoms. No attorney can provide a reliable estimate before bellwether trials conclude.

The decision tree: settle, opt out, or wait for trial

If and when a settlement structure is announced (likely 2028 to 2029), individual plaintiffs face a choice:

Option 1: Accept the settlement.

• Receive a tiered payout based on injury severity (likely $10,000 to $1 million+ depending on tier)
• Waive the right to pursue individual trial
• Payout occurs within 6 to 18 months of accepting the settlement
• No risk of receiving nothing (as long as you meet eligibility criteria)
• Attorney fees typically 30% to 40% of the settlement amount

Option 2: Opt out and pursue individual trial.

• Retain the right to seek a larger jury verdict
• Face the risk of losing at trial and receiving nothing
• Trial may not occur for 2 to 5 years after opting out
• Higher attorney fees and litigation costs
• Potential for significantly larger payout if you win (juries have awarded $5 million+ in similar cases)

Option 3: Wait and see.

• Do not immediately accept the settlement
• Observe additional bellwether trial outcomes
• Join a later settlement round if terms improve
• Risk that the settlement offer is withdrawn or terms worsen

The decision tree:

If your gastroparesis is Tier 3 or 4 (severe, well-documented, required hospitalization or surgery):

• Consider opting out and pursuing individual trial if early bellwether verdicts favor plaintiffs
• The settlement offer may undervalue your claim relative to jury verdict potential
• Consult with your attorney about trial risk vs settlement certainty

If your gastroparesis is Tier 1 or 2 (mild to moderate, managed with medication or diet changes):

• Accept the settlement
• The cost and risk of individual trial likely exceed the incremental benefit
• Settlement provides certainty and faster resolution

If your gastroparesis resolved after discontinuing the medication and you have minimal ongoing symptoms:

• Expect a low settlement offer (Tier 1, $10,000 to $50,000)
• Decide whether the payout justifies the administrative burden of participating
• Consider whether your documentation is strong enough to meet eligibility criteria

If you cannot produce objective medical evidence (gastric emptying study, endoscopy, hospitalization records):

• You may not qualify for settlement
• Consult with your attorney about whether joining the litigation is worthwhile

The FormBlends clinical pattern we observe: patients who discontinued semaglutide or tirzepatide within the first 8 weeks due to severe nausea or vomiting often did not pursue formal gastroparesis diagnosis. Without diagnostic testing, these patients may struggle to meet settlement eligibility criteria, even if they experienced genuine symptoms. The lesson: if you suspect medication-induced gastroparesis, document it with objective testing before discontinuing treatment.

When you should NOT join the litigation

Joining the Ozempic litigation is not appropriate for every patient who experienced gastrointestinal side effects. The following situations do not support a viable claim:

1. Transient nausea or vomiting that resolved within 4 to 8 weeks.

Nausea and vomiting are listed side effects of GLP-1 medications, occurring in 20% to 40% of patients during titration. These symptoms are expected, disclosed on the label, and typically resolve as the body adapts. They do not constitute failure to warn.

Gastroparesis is distinct. It is a chronic motility disorder diagnosed by gastric emptying study showing delayed emptying beyond 4 hours. Transient nausea is not gastroparesis.

2. Pre-existing gastroparesis or diabetic gastropathy.

If you had documented gastroparesis or gastric motility issues before starting a GLP-1 medication, you cannot claim the medication caused the condition. Defendants will argue the medication worsened a pre-existing condition, which is not a failure-to-warn claim.

3. Symptoms that began more than 12 months after discontinuing the medication.

Causation requires temporal proximity. If you stopped taking Ozempic in 2022 and developed gastroparesis symptoms in 2025, the causal link is weak. Defendants will argue other factors caused the condition.

4. Lack of objective diagnostic evidence.

If you did not undergo gastric emptying scintigraphy, upper endoscopy, or other diagnostic testing, you cannot prove gastroparesis. Subjective symptoms alone are insufficient.

5. Concurrent use of other medications known to cause gastroparesis.

Opioids, anticholinergics, tricyclic antidepressants, and other medications delay gastric emptying. If you were taking these medications concurrently with a GLP-1 agonist, causation becomes difficult to prove.

6. You are still benefiting from GLP-1 therapy and do not want to discontinue.

Joining the litigation may complicate your ongoing treatment relationship. Some patients fear that filing a lawsuit will prevent them from accessing GLP-1 medications in the future (this is not legally true, but it creates practical complications). If you are still taking and benefiting from semaglutide or tirzepatide, consider whether litigation aligns with your treatment goals.

The honest assessment: if your symptoms were mild, transient, and resolved after dose adjustment or discontinuation, the litigation is unlikely to result in meaningful compensation. The administrative burden and attorney fees may exceed any potential payout.

The gastroparesis severity spectrum and how it affects payout

Gastroparesis exists on a spectrum from mild to catastrophic. Settlement structures (and jury verdicts) tier payouts based on objective severity measures. Understanding where your case falls on the spectrum helps set realistic expectations.

Mild gastroparesis (Grade 1):

• Symptoms: Occasional nausea, early satiety, mild bloating
• Gastric emptying study: 10% to 15% retention at 4 hours (normal is under 10%)
• Management: Dietary changes (small, frequent meals; low-fat, low-fiber diet)
• Impact on daily life: Minimal; able to work and perform normal activities
• Projected settlement tier: $10,000 to $50,000

Moderate gastroparesis (Grade 2):

• Symptoms: Frequent nausea and vomiting (1 to 3 times per week), weight loss, abdominal pain
• Gastric emptying study: 15% to 35% retention at 4 hours
• Management: Prokinetic medications (metoclopramide), antiemetics, dietary modification
• Impact on daily life: Moderate; some work absences, reduced quality of life
• Projected settlement tier: $50,000 to $250,000

Severe gastroparesis (Grade 3):

• Symptoms: Daily vomiting, inability to maintain nutrition, significant weight loss (more than 10% body weight), dehydration
• Gastric emptying study: Greater than 35% retention at 4 hours
• Management: Hospitalization for IV fluids and nutrition, gastric electrical stimulation (gastric pacemaker), jejunal feeding tube
• Impact on daily life: Severe; unable to work, requires ongoing medical care
• Projected settlement tier: $250,000 to $1 million

Catastrophic gastroparesis (Grade 4):

• Symptoms: Total gastric paralysis, complete inability to tolerate oral intake, recurrent hospitalizations
• Gastric emptying study: Greater than 50% retention at 4 hours, or inability to complete study due to vomiting
• Management: Permanent feeding tube (J-tube or G-J tube), total parenteral nutrition (TPN), possible gastrectomy
• Impact on daily life: Catastrophic; permanent disability, loss of employment, ongoing medical expenses exceeding $100,000 per year
• Projected settlement tier: $1 million to $5 million

The severity grading above is based on the Gastroparesis Cardinal Symptom Index (GCSI) and American Neurogastroenterology and Motility Society guidelines (Camilleri et al., Clinical Gastroenterology and Hepatology 2013). Settlement structures in pharmaceutical MDLs typically adopt similar grading systems to tier payouts.

The pattern we observe in compounded GLP-1 patient consultations: most patients who report "gastroparesis symptoms" fall into Grade 1 or Grade 2. Severe and catastrophic cases are rare but highly visible in litigation because they generate the largest settlements. Patients with Grade 1 symptoms should not expect six-figure payouts.

What happens if Novo Nordisk refuses to settle

Settlement is not guaranteed. Novo Nordisk and Eli Lilly may choose to litigate every case individually rather than agree to a global settlement. This is the "fight to the end" strategy, and it has precedent.

Why a manufacturer might refuse to settle:

1. Strong defense on causation. If bellwether trials produce mostly defense verdicts, manufacturers have little incentive to settle. They may conclude that juries are not persuaded by plaintiffs' causation evidence.

1. Preemption defense. If courts rule that federal law preempts state failure-to-warn claims, the litigation collapses and no settlement is needed.

1. Financial calculation. Novo Nordisk may determine that the cost of settling (potentially billions of dollars across thousands of plaintiffs) exceeds the cost of litigating each case individually, even if they lose some trials.

1. Deterrence. Settling a high-profile MDL can encourage future litigation. Manufacturers sometimes refuse to settle to signal that they will fight every claim, discouraging future plaintiffs and attorneys.

What happens if no settlement is reached:

• The MDL continues indefinitely
• Each plaintiff's case is remanded to the original filing jurisdiction for individual trial
• Trials occur over 5 to 10 years
• Some plaintiffs win, some lose
• Plaintiffs who win receive jury verdicts (potentially larger than settlement offers)
• Plaintiffs who lose receive nothing and may owe court costs
• The litigation drags on for a decade or more

The Taxotere litigation is an example. Sanofi refused to agree to a global settlement and instead litigated individual cases. Some plaintiffs received multi-million-dollar verdicts. Others lost at trial. The litigation is still ongoing in 2026, a decade after the MDL was established.

The Zantac litigation is the extreme example. The court excluded plaintiffs' expert testimony, and the entire MDL was dismissed. Thousands of plaintiffs received nothing.

For the Ozempic litigation, the most likely outcome is a settlement structure between 2028 and 2030. But refusal to settle is a real possibility, and plaintiffs should understand that joining the litigation does not guarantee compensation.

The FormBlends 3-Question Pre-Litigation Checklist

Before joining the Ozempic litigation, ask yourself three questions. If you answer "no" to any of them, consult with an attorney about whether your claim is viable.

Question 1: Do I have objective diagnostic evidence of gastroparesis?

Objective evidence includes:

• Gastric emptying scintigraphy showing delayed emptying (greater than 10% retention at 4 hours)
• Upper endoscopy ruling out mechanical obstruction
• Hospitalization records documenting severe nausea, vomiting, or dehydration
• Prescription records for prokinetic medications or antiemetics

Subjective symptoms alone (nausea, bloating, feeling full) are not sufficient. You must have diagnostic testing that confirms gastroparesis.

Question 2: Did my symptoms begin while I was taking a GLP-1 medication, and did they persist after discontinuation?

Temporal relationship is necessary for causation. If symptoms began before starting the medication, or more than 6 months after discontinuing, the causal link is weak.

The strongest claims involve symptoms that began within 4 to 12 weeks of starting the medication and persisted for at least 6 months after discontinuation.

Question 3: Can I rule out other causes of gastroparesis?

Other common causes include:

• Diabetes (diabetic gastropathy affects 30% to 50% of long-term diabetics)
• Opioid use
• Post-surgical complications (especially gastric or esophageal surgery)
• Autoimmune conditions (scleroderma, lupus)
• Neurological disorders (Parkinson's, multiple sclerosis)
• Eating disorders

If you have one of these conditions, causation becomes more difficult to prove. Defendants will argue that the alternative cause, not the GLP-1 medication, caused your gastroparesis.

If you answer "yes" to all three questions, your claim is likely viable. If you answer "no" to any question, consult with an attorney before investing time and resources in the litigation.

FAQ

When will the Ozempic lawsuit be settled? Based on pharmaceutical litigation precedent, the Ozempic gastroparesis lawsuits will likely reach settlement discussions between 2027 and 2029, with final resolution by 2030 to 2031. Settlement timing depends on bellwether trial outcomes, which are expected to begin in late 2026 or early 2027.

How much will the Ozempic settlement pay per person? No settlement has been announced as of April 2026. If a settlement structure emerges, payouts will likely be tiered by injury severity, ranging from $10,000 for mild transient symptoms to $1 million or more for catastrophic cases requiring permanent feeding tubes or gastric pacemakers.

Can I still join the Ozempic lawsuit in 2026? Yes. The litigation is ongoing and accepting new plaintiffs. However, statutes of limitations vary by state (typically 2 to 3 years from injury discovery). If your symptoms began in 2022 or earlier, consult with an attorney immediately to determine whether your claim is time-barred.

What is a bellwether trial and why does it matter? A bellwether trial is a representative case selected from the MDL and tried to verdict. Bellwether outcomes establish valuation benchmarks and inform settlement negotiations. The first Ozempic bellwether trials are expected in late 2026 or early 2027.

Do I need a lawyer to join the Ozempic lawsuit? Yes. MDL cases require representation by an attorney admitted to practice in the MDL jurisdiction (Eastern District of Pennsylvania). Most plaintiffs' attorneys work on contingency (no upfront fees, 30% to 40% of any settlement or verdict).

What if I am still taking Ozempic or Wegovy? You can join the litigation while still taking the medication, but it complicates your claim. Continuing to take a medication you allege caused you harm undermines the argument that the harm is severe. Consult with your prescribing provider and an attorney before making treatment changes.

Will joining the lawsuit affect my ability to get GLP-1 medications in the future? Legally, no. Joining the lawsuit does not prevent you from being prescribed semaglutide, tirzepatide, or other GLP-1 medications. Practically, it may create discomfort in your provider relationship. Some patients choose to wait until they have discontinued treatment before joining litigation.

What is the difference between the Ozempic lawsuit and the Mounjaro lawsuit? Both are consolidated in the same MDL (MDL No. 3094) because they involve the same core allegation: GLP-1 receptor agonists cause gastroparesis and manufacturers failed to warn. Ozempic and Wegovy contain semaglutide (Novo Nordisk). Mounjaro and Zepbound contain tirzepatide (Eli Lilly). The lawsuits target different manufacturers but are litigated together.

Can I sue if I took compounded semaglutide instead of brand-name Ozempic? This is a complex question. Compounded medications are prepared by pharmacies, not manufactured by Novo Nordisk or Eli Lilly. If you took compounded semaglutide, your claim may be against the compounding pharmacy rather than the drug manufacturer. Consult with an attorney about whether your specific situation supports a claim.

What happens if the lawsuit is dismissed like Zantac? If the court excludes plaintiffs' expert testimony on causation (as happened in the Zantac MDL), the litigation could be dismissed and plaintiffs would receive nothing. This is a real risk. The strength of plaintiffs' expert evidence will determine whether the litigation survives Daubert challenges.

How do I know if my gastroparesis was caused by Ozempic or something else? Causation requires ruling out alternative explanations. Your medical records should document that symptoms began after starting the medication, worsened with dose escalations, and improved (or at least did not worsen) after discontinuation. Diagnostic testing should rule out other causes (diabetes, opioid use, mechanical obstruction). An expert witness will review your records and provide an opinion on causation.

Will I have to testify in court? If you accept a settlement, no. If you opt out and pursue individual trial, yes. Bellwether plaintiffs are selected by the court and must testify. Most plaintiffs in an MDL never testify because their cases settle or are resolved through the bellwether process.

Can I get compensation if my symptoms resolved after stopping Ozempic? Possibly, but the payout will be lower (likely Tier 1, $10,000 to $50,000). Settlement structures typically prioritize plaintiffs with ongoing, permanent injuries. If your symptoms resolved, you may still qualify for compensation if you can document that you experienced genuine gastroparesis (confirmed by diagnostic testing) during treatment.

What is the statute of limitations for filing an Ozempic lawsuit? Statutes of limitations vary by state, typically 2 to 3 years from the date you discovered (or should have discovered) the injury. If you were diagnosed with gastroparesis in 2023, the deadline to file is likely 2025 or 2026. Consult with an attorney immediately if you are near the deadline.

Do I have to stop taking Ozempic to join the lawsuit? No, but continuing treatment while claiming the medication harmed you weakens your case. Defendants will argue that if the harm were severe, you would have discontinued the medication. Most plaintiffs in the MDL have already stopped taking GLP-1 medications.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Camilleri M et al. Clinical guideline: management of gastroparesis. American Journal of Gastroenterology. 2013.
4. Halawi H et al. Gastroparesis: pathophysiology, clinical manifestations, and diagnosis. UpToDate. 2024.
5. U.S. Judicial Panel on Multidistrict Litigation. Transfer Order MDL No. 3094, In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation. February 2024.
6. Parkman HP et al. Clinical features of idiopathic gastroparesis vary with sex, body mass, symptom onset, delay in gastric emptying, and gastroparesis severity. Gastroenterology. 2011.
7. Sanger GJ et al. Ghrelin, gastroparesis, and GLP-1 receptor agonists. Neurogastroenterology & Motility. 2022.
8. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
9. Friedenberg FK et al. The utility of gastric emptying scintigraphy in the evaluation of gastroparesis. Digestive Diseases and Sciences. 2008.
10. Revicki DA et al. Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Alimentary Pharmacology & Therapeutics. 2003.
11. Camilleri M et al. Gastroparesis. Nature Reviews Disease Primers. 2018.
12. Bharucha AE et al. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2013.
13. Parrish CR et al. Practical approach to the nutritional management of gastroparesis. Diabetes Educator. 2007.
14. McCallum RW et al. Gastric electrical stimulation with Enterra therapy improves symptoms from diabetic gastroparesis in a prospective study. Clinical Gastroenterology and Hepatology. 2010.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Risperdal, Xarelto, Taxotere, Elmiron, and Zantac are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.

Legal Disclaimer. This article provides general information about ongoing litigation and is not legal advice. FormBlends does not provide legal services or referrals to litigation attorneys. Consult with a qualified attorney about your specific situation. Statements about settlement timelines and amounts are projections based on historical precedent and do not constitute guarantees or predictions about actual outcomes.